Dai H. Chung: Delivering Lyfgenia to Pediatric Patients With Sickle Cell Disease
Dai H. Chung, Chief Medical Executive and Surgeon-in-Chief at Children’s Health, shared a post on LinkedIn:
“‘The process is complex, but the results can be dramatic.’
That observation from colleague Tiffany Simms-Waldrip, Pediatric Hematologist and Oncologist at Children’s Health and Clinical Associate Professor at UT Southwestern Medical Center, reflects the promise and the complexity of Lyfgenia for sickle cell disease.
As one of fewer than 10 pediatric centers in and around Texas offering Lyfgenia for sickle cell disease, Children’s Health has already treated two patients.
This Children’s Health Research Library article provides an inside look at the expertise, collaboration and commitment required to deliver a complex therapy with life-changing potential.”
Stay updated with Hemostasis Today.
-
Oct 25, 2026, 02:17Marilyn Baffoe-Bonnie: What Does It Mean to Be Cured of Sickle Cell Disease?
-
Oct 25, 2026, 02:15Tamara Stipcevic: A Hand-Powered Device for Rapid Blood Typing and Hematocrit Estimation
-
Oct 25, 2026, 02:14Rhonda Patrick: Microplastics Generate Damaging Free Radicals Simply by Contacting Water
-
Oct 25, 2026, 02:12Chokri Ben Lamine: Rilzabrutinib – Oral BTK Inhibitor for ITP
-
Oct 25, 2026, 02:12Michael H. Tomasson: Self-Experimentation That Revealed the Immune Mechanism of ITP
-
Oct 25, 2026, 02:10Nabiha Huq Saifee: Do You Help Make Platelet Transfusion Decisions Before Lumbar Puncture?
-
Oct 25, 2026, 02:09Sebastian Szmit: Congratulations to Isabelle Mahé on Her New Cardio-Oncology Paper
-
Oct 24, 2026, 16:57Pall T. Onundarson: Fiix Prothrombin Time Advancing Precision in Anticoagulation Management
-
Oct 24, 2026, 16:42Mark-Anthony Johnson: Blood Type Awareness and Emergency Transfusion